Coldstream Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.1M Buy
74,217
+727
+1% +$161K 0.2% 66
2025
Q4
$16.8M Buy
73,490
+1,980
+3% +$451K 0.22% 66
2025
Q3
$16.6M Sell
71,510
-1,322
-2% -$269K 0.22% 64
2025
Q2
$13.5M Buy
72,832
+6,227
+9% +$1.16M 0.22% 70
2025
Q1
$14M Buy
66,605
+1,377
+2% +$268K 0.3% 56
2024
Q4
$11.6M Buy
65,228
+3,157
+5% +$580K 0.25% 57
2024
Q3
$12.2M Buy
62,071
+3,405
+6% +$635K 0.26% 55
2024
Q2
$10.1M Buy
58,666
+602
+1% +$99.7K 0.25% 56
2024
Q1
$10.6M Buy
58,064
+2,995
+5% +$516K 0.27% 51
2023
Q4
$8.53M Buy
55,069
+2,248
+4% +$328K 0.24% 57
2023
Q3
$7.87M Buy
52,821
+1,839
+4% +$270K 0.26% 59
2023
Q2
$6.87M Sell
50,982
-1,451
-3% -$213K 0.22% 69
2023
Q1
$8.36M Buy
52,433
+1,222
+2% +$187K 0.28% 55
2022
Q4
$8.28M Buy
+51,211
New +$7.85M 0.3% 52
2022
Q2
$8.51M Buy
55,581
+2,244
+4% +$343K 0.33% 54
2022
Q1
$8.65M Sell
53,337
-2,432
-4% -$353K 0.3% 53
2021
Q4
$7.55M Buy
55,769
+14,601
+35% +$1.72M 0.24% 64
2021
Q3
$3.61M Sell
41,168
-411
-1% -$47K 0.17% 82
2021
Q2
$4.68M Buy
41,579
+824
+2% +$92.8K 0.19% 83
2021
Q1
$4.41M Buy
40,755
+29,286
+255% +$3.13M 0.26% 63
2020
Q4
$1.23M Sell
11,469
-26,370
-70% -$2.53M 0.07% 133
2020
Q3
$3.31M Sell
37,839
-187
-0.5% -$17.6K 0.28% 59
2020
Q2
$3.73M Sell
38,026
-1,391
-4% -$122K 0.34% 45
2020
Q1
$3M Sell
39,417
-1,379
-3% -$117K 0.33% 50
2019
Q4
$3.61M Buy
40,796
+1,508
+4% +$125K 0.3% 61
2019
Q3
$2.98M Sell
39,288
-164
-0.4% -$11.2K 0.25% 75
2019
Q2
$2.87M Buy
39,452
+676
+2% +$53.1K 0.24% 80
2019
Q1
$3.13M Sell
38,776
-1,735
-4% -$142K 0.27% 72
2018
Q4
$3.73M Buy
40,511
+865
+2% +$76.1K 0.36% 52
2018
Q3
$3.75M Buy
39,646
+2,302
+6% +$218K 0.34% 53
2018
Q2
$3.46M Buy
37,344
+506
+1% +$49.4K 0.35% 48
2018
Q1
$3.49M Sell
36,838
-5,221
-12% -$574K 0.38% 43
2017
Q4
$4.07M Buy
42,059
+1,690
+4% +$159K 0.44% 42
2017
Q3
$3.59M Buy
40,369
+4,264
+12% +$325K 0.42% 47
2017
Q2
$2.62M Buy
36,105
+2,590
+8% +$174K 0.34% 56
2017
Q1
$2.18M Sell
33,515
-9,169
-21% -$576K 0.3% 67
2016
Q4
$2.67M Buy
42,684
+1,449
+4% +$88.4K 0.44% 38
2016
Q3
$2.6M Sell
41,235
-1,486
-3% -$96.2K 0.46% 36
2016
Q2
$2.65M Sell
42,721
-800
-2% -$48.7K 0.47% 36
2016
Q1
$2.49M Sell
43,521
-3,841
-8% -$214K 0.45% 33
2015
Q4
$2.81M Buy
47,362
+718
+2% +$41.4K 0.61% 24
2015
Q3
$2.54M Buy
46,644
+371
+0.8% +$24.1K 0.68% 26
2015
Q2
$3.11M Sell
46,273
-654
-1% -$42.7K 0.81% 20
2015
Q1
$2.75M Buy
46,927
+10,017
+27% +$605K 0.76% 29
2014
Q4
$2.42M Sell
36,910
-2,827
-7% -$178K 0.67% 33
2014
Q3
$2.29M Buy
39,737
+699
+2% +$38.8K 0.65% 33
2014
Q2
$2.2M Sell
39,038
-1,820
-4% -$95.5K 0.65% 32
2014
Q1
$2.1M Buy
40,858
+599
+1% +$30.3K 0.68% 34
2013
Q4
$2.13M Sell
40,259
-503
-1% -$24.7K 0.69% 30
2013
Q3
$1.82M Buy
40,762
+393
+1% +$17.4K 0.6% 40
2013
Q2
$1.67M Buy
+40,369
New +$1.77M 0.56% 47

Other funds holding ABBV

Coldstream Capital Management's ABBV Position: Q1 2026 in Review

Coldstream Capital Management increased its AbbVie (ABBV) stake by 0.99% in Q1 2026, buying an estimated $161K and bringing the position to 74,217 shares worth $16.1M. The position accounts for 0.2% of the portfolio, ranked #66.

Coldstream Capital Management first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $16.8M in Q4 2025. 4,090 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Coldstream Capital Management held 74,217 shares of AbbVie worth $16.1M as of Q1 2026.
  • Coldstream Capital Management bought 727 AbbVie shares in Q1 2026, an estimated $161K.
  • AbbVie made up 0.2% of Coldstream Capital Management's portfolio in Q1 2026, its #66 holding.
  • Coldstream Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • Coldstream Capital Management's AbbVie position peaked at $16.8M in Q4 2025.
  • 4,090 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.